Biotechnology · Rockville, Maryland, United States
$7.16
+4.07% (+$0.28)2026-10-15
Smart-Money SignalNeutral · 52/100— Insiders are net buyers over 90 days ($949K, 2 buys vs 0 sales)
Revenue$108.0M
Net Income$22.7M
EPS$-1.28
Market Cap$387.8M
Price Performance
Historical data including institutional events
Company Profile
C
Curran Simpson
CEO & Executive Director
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The companyâs products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202 for the treatment of Duchenne muscular dystrophy, as well as RGX-121 for the treatment of mucopolysaccharidosis type II. It also develops RGX-111 for the treatment of mucopolysaccharidosis type I. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 and with Nippon Shinyaku Co., Ltd. to develop RGX-121 and RGX-111 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.
- Founded
- 2008
- Employees
- 371
- Headquarters
- Rockville, Maryland, United States
- Website
- www.regenxbio.com
Peer ComparisonRevenue ($B)
▾Loading company sections...